Opus Genetics (IRD) Interest Coverage Ratio (2020 - 2026)

Opus Genetics (IRD) reported Interest Coverage Ratio of 208.17 for Q1 2026, down 10.88% quarter-over-quarter from 187.75 in Q4 2025.

Opus Genetics (IRD) Interest Coverage Ratio (2020 - 2026) Analysis & Trends

Opus Genetics (IRD) has 5 years of Interest Coverage Ratio data on file, last reported at 208.17 in Q1 2026.

Interest Coverage Ratio for Q1 2026 came in at 208.17, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 217.34 (changed N/A YoY), and the FY2025 annual result was 299.22, changed N/A from the prior year.
Interest Coverage Ratio declined to 208.17 in Q1 2026 per IRD's latest filing, from 187.75 in the prior quarter.
Over five years, Interest Coverage Ratio peaked at 122.22 in Q3 2025 and troughed at 1301.6 in Q1 2022.
A 3-year average of 610.85 and a median of 208.17 in 2026 frame the typical range for Interest Coverage Ratio.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Cover (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	3.58
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	11.50
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-258.33
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	547.67
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	11.79
10	Opus Genetics	355.39 Mn	295.43 Mn	-	-208.17

Download Data